文献速递脊柱关节炎

miR-10b-5p 是强直性脊柱炎 Th17 细胞中存在的新型 Th17 调控因子

miR-10b-5p is a novel Th17 regulator present in Th17 cells from ankylosing spondylitis.
PubMed 文献 · Ann Rheum Dis · 2016-12-30

研究对强直性脊柱炎(AS)患者和健康对照的 IL-17A 产生 CD4+ T 细胞进行 miR 测序和 qPCR 验证,发现 AS Th17 细胞具有特定 miR 表达特征,miR-10b 通过靶向 MAP3K7 抑制 IL-17A 产生,可能作为负反馈环路并成为抑制 AS 致病性 Th17 细胞的潜在治疗候选。

要点

  • AS Th17 细胞 miR 特征为 miR-155-5p、miR-210-3p 和 miR-10b 上调。
  • miR-10b 靶向 MAP3K7,过表达 miR-10b 或沉默 MAP3K7 均抑制 IL-17A 产生。
  • miR-10b 可能作为负反馈环路抑制 IL-17A,是潜在治疗候选。

核心结论

  • AS Th17 细胞具有特定 miR 特征,miR-10b 通过靶向 MAP3K7 抑制 IL-17A,可能作为负反馈环路并成为潜在治疗候选。

研究设计与样本

  • 研究对 AS 患者和健康对照的 IL-17A 产生 CD4+ T 细胞进行 FACS 分选,用于 miR 测序和 qPCR 验证。
  • 通过 miR 模拟物表达、细胞因子检测、转录组分析、qPCR 和荧光素酶试验确定 miR-10b 功能。

主要发现

  • AS Th17 细胞 miR 特征表现为 miR-155-5p、miR-210-3p 和 miR-10b 上调。
  • miR-10b 在体外分化的 Th17 细胞中短暂诱导,此前未在 Th17 细胞中描述。
  • 转录组、qPCR 和荧光素酶试验提示 MAP3K7 是 miR-10b 的靶点。
  • miR-10b 过表达和 MAP3K7 沉默均抑制总 CD4 和分化中 Th17 细胞的 IL-17A 产生。

临床怎么用

  • miR-10b 是抑制 AS 患者致病性 Th17 细胞功能的潜在治疗候选。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the microRNA (miR) signature in ankylosing spondylitis (AS) T helper (Th)17 cells. METHODS: Interleukin (IL)-17A-producing CD4+ T cells from patients with AS and healthy controls were FACS-sorted for miR sequencing and qPCR validation. miR-10b function was determined by miR mimic expression followed by cytokine measurement, transcriptome analysis, qPCR and luciferase assays. RESULTS: AS Th17 cells exhibited a miR signature characterised by upregulation of miR-155-5p, miR-210-3p and miR-10b. miR-10b has not been described previously in Th17 cells and was selected for further characterisation. miR-10b is transiently induced in in vitro differentiated Th17 cells. Transcriptome, qPCR and luciferase assays suggest that MAP3K7 is targeted by miR-10b. Both miR-10b overexpression and MAP3K7 silencing inhibited production of IL-17A by both total CD4 and differentiating Th17 cells. CONCLUSIONS: AS Th17 cells have a specific miR signature and upregulate miR-10b in vitro. Our data suggest that miR-10b is upregulated by proinflammatory cytokines and may act as a feedback loop to suppress IL-17A by targeting MAP3K7. miR-10b is a potential therapeutic candidate to suppress pathogenic Th17 cell function in patients with AS.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Chen L, Al-Mossawi MH, Ridley A, et al. miR-10b-5p is a novel Th17 regulator present in Th17 cells from ankylosing spondylitis. Ann Rheum Dis. 2016. PMID: 28039186. doi:10.1136/annrheumdis-2016-210175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。